Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3912
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRevesz, T.en
dc.contributor.authorLaw, T.en
dc.contributor.authorOng, E.en
dc.contributor.authorHeatley, S. L.en
dc.contributor.authorMcClure, B. J.en
dc.contributor.authorMeyer, C.en
dc.contributor.authorMarschalek, R.en
dc.contributor.authorHenderson, M. J.en
dc.contributor.authorCross, S.en
dc.contributor.authorWhite, D. L.en
dc.contributor.authorKotecha, R. S.en
dc.contributor.authorKhaw, S. L.en
dc.contributor.authorFraser, C.en
dc.contributor.authorBateman, C. M.en
dc.contributor.authorTrahair, T. N.en
dc.contributor.authorMitchell, R.en
dc.contributor.authorVenn, N. C.en
dc.contributor.authorChamberlain, J.en
dc.contributor.authorSutton, R.en
dc.contributor.authorPozza, L. D.en
dc.date.accessioned2022-11-07T23:47:24Z-
dc.date.available2022-11-07T23:47:24Z-
dc.date.issued2021en
dc.identifier.citation68, (5), 2021en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/3912-
dc.description.abstractWe report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). Four patients successfully received CD19-directed chimeric antigen receptor T-cell therapy despite prior blinatumomab exposure. Inferior 2-year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A-rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B-ALL respond to blinatumomab and factors such as blast genotype may affect prognosis.L20106060732021-03-08 <br />en
dc.language.isoenen
dc.relation.ispartofPediatric Blood and Canceren
dc.titleOutcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomaben
dc.typeArticleen
dc.identifier.doi10.1002/pbc.28922en
dc.subject.keywordsleukemia remissionen
dc.subject.keywordsmaleen
dc.subject.keywordsminimal residual diseaseen
dc.subject.keywordsmultiple cycle treatmenten
dc.subject.keywordsoverall survivalen
dc.subject.keywordspre B lymphocyteen
dc.subject.keywordspriority journalen
dc.subject.keywordsprogression free survivalen
dc.subject.keywordsrelapsed refractory acute lymphoblastic leukemiaen
dc.subject.keywordstreatment responseen
dc.subject.keywordstumor geneen
dc.subject.keywordssalvage therapyen
dc.subject.keywords2016-004674-17NCT02393859en
dc.subject.keywordsblinatumomaben
dc.subject.keywordsCD19 antigenen
dc.subject.keywordsdasatiniben
dc.subject.keywordsinotuzumab ozogamicinen
dc.subject.keywordsmixed lineage leukemia proteinen
dc.subject.keywordsnilotiniben
dc.subject.keywordsvenetoclaxen
dc.subject.keywordsacute lymphoblastic leukemiaen
dc.subject.keywordsarticleen
dc.subject.keywordsAustraliaen
dc.subject.keywordscancer prognosisen
dc.subject.keywordscancer recurrenceen
dc.subject.keywordscancer survivalen
dc.subject.keywordsCD3+ T lymphocyteen
dc.subject.keywordschilden
dc.subject.keywordschildhood leukemiaen
dc.subject.keywordschimeric antigen receptor T-cell immunotherapyen
dc.subject.keywordsclinical articleen
dc.subject.keywordsclinical outcomeen
dc.subject.keywordsclinical trialen
dc.subject.keywordsdisease burdenen
dc.subject.keywordsdrug exposureen
dc.subject.keywordsevent free survivalen
dc.subject.keywordsfemaleen
dc.subject.keywordsfollow upen
dc.subject.keywordsgene rearrangementen
dc.subject.keywordsgenetic risken
dc.subject.keywordshematopoietic stem cell transplantationen
dc.subject.keywordshumanen
dc.subject.keywordskmt2a geneen
dc.subject.keywordsleukemia relapseen
dc.relation.urlhttps://www.embase.com/search/results?subaction=viewrecord&id=L2010606073&from=exporthttp://dx.doi.org/10.1002/pbc.28922 |en
dc.identifier.risid2801en
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.openairetypeArticle-
item.grantfulltextnone-
item.fulltextNo Fulltext-
Appears in Sites:Children's Health Queensland Publications
Show simple item record

Page view(s)

84
checked on Apr 29, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.